GlassScriptPhysician profile
April D Ross
NPI 1487960092
$94,573.64
in general payments reported to CMS, 2019-2025
23 companies · $241 in 2025
The $241 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $69K · 2022: $23K · 2023: $358 · 2024: $1,826 · 2025: $241.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,843 · Travel and Lodging: $582.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,843.04 |
| Travel and Lodging | $582.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $65,954.99 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $19,878.96 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $3,012.88 | 2022 | |
| Allergan, INC. | $2,706.32 | 2021-2022 | |
| Merz North America, INC. | $1,712.45 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $572.71 | 2021-2022 | |
| Amgen INC. | $189.77 | 2021-2022 | |
| Galderma Laboratories, L.P. | $79.52 | 2023 | |
| Amneal Pharmaceuticals LLC | $73.80 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $64.69 | 2021 | |
| Lilly USA, LLC | $47.70 | 2021-2022 | |
| Ucb, INC. | $44.81 | 2021 | |
| Merz Pharmaceuticals, LLC | $44.25 | 2021-2022 | |
| Emd Serono, INC. | $34.64 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $33.59 | 2021-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $28.19 | 2021 | |
| Biogen, INC. | $16.91 | 2021 | |
| Genentech USA, INC. | $15.08 | 2023 | Ocrevus |
| Xeris Pharmaceuticals, INC. | $14.10 | 2022 | |
| Sunovion Pharmaceuticals INC. | $13.04 | 2021 | |
| Alexion Pharmaceuticals, INC. | $12.36 | 2021 | |
| Acadia Pharmaceuticals INC | $11.66 | 2021 | |
| Catalyst Pharmaceuticals, INC. | $11.22 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw April Ross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.